Two column liquid Chromatographie (HPLC) methods for thexietermination of ciprofloxacin and three metabolites are described. Both use reversed phase chromatography, the stationary phase being Nucleosil 5C18. Method A separates ciprofloxacin, metabolite Ml and another metabolite of unknown structure using fluorometric detection. Method B allows the determinations of metabolite M3 (oxo-ciprofloxacin) in urine by UV absorption. Serum was deproteinised with acetonitrile. Urine was diluted with buffer solution. The detection limit of ciprofloxacin was 0.010 mg/1 serum and 0.2 mg/1 urine and for the metabolite M3, l mg/1 urine. Within-batch precision (coefficient of Variation) for ciprofloxacin in serum was 0.8 to 2.4% and between-batch precision 4.8 to 9.3%. In urine within-batch precision was 1.7 to 2.1% and between-batch precision 2.4 to 7.2%. Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 ± 2.6%, 97.2 + 1.1% and 95.0 ± 1.8% and from urine 99.6%. Results obtained by HPLC (method A) were compared with those from a Standard microbiological assay by means of bivariäte regression analysis. In 12 subsets of data the slope of the regression line varied from 1.042 to 1.556. Significantly higher results from the microbiological assay were probably due to the presence of microbiologically active metabolites. We conclude that HPLC is the more specific method of determination. The described methods were applied for pharmacokinetic studies and therapeutic drug monitoring. 
Introduction
Ciprofloxacin (l -cyclopropyl-6-fluoro-l ,4-dihydro-4-oxo-7-(l-piperazinyl-)-quinolone-3-carboxylic acid; fig. 1 ) belongs to the recent derivatives of nalidixic acid, called gyrase inhibitors. It has remarkable antimicrobial activity (1 -8) and is presently under clinical evaluation. This paper describes the determination of ciprofloxacin and three of its metabolites in human body fluids. The method has been extensively used in pharmacokinetic studies (9) (10) (11) and for therapeutic drug monitoring. 
Methods

Chemicals
Reference material of ciprofloxacin (lot no. 907452, potency 842 mg/g) and of several metabolites (cf. fig. 1 ) were kindly supplied by Bayer AG, Wuppertal, FRG. Tetrabutyl ammonium phosphate (PIC A, low UV grade) was obtained from Waters GmbH., Eschborn, FRG. Unless otherwise stated reagents and solvents were of reagent grade purity supplied by E. Merck AG, Darmstadt, FRG. Redistilled water was used in all experiments.
Volunteers and patients
Volunteers participating in pharmacokinetic studies were instructed not to take any drugs or caffeine-or quinine-containing beverages 24 h before and during the study. Patients were on a regul r hospital diet and usually received 4 to 6 drugs concomitantly which were recorded for ppssible analytical interferences. All volunteers gave written informed consent according to legal requirements in the FRG.
Blood was taken without additives and was allowed to clot at room temperature. It was subsequently centrifuged at 3000 g for 10 min. Serum and urine specimens for chromatography were stored at -80°C for no more than 2 months before processing. The microbiological determination was performed on the day of sampling or on the day thereafter. Method A 125 ml acetonitrile were mixed with tetrabutyl ammonium phosphate solution and made up to a final Volume of l1.
Method B 220 ml acetonitrile were mixed with tetrabutyl ammonium phosphate solution and made up to a final volume of 11.
The mobile phases were filtered before use and were recycled for no mpre than 3 days of continuous Operation.
Preparation of Standards
A stock solution of 10 mg/1 ciprofloxacin was made by diluting 11.88 mg of reference material in water. The stock solution was stable at 4 °C for at least l week. Working Standards (0.010 to 3.000 mg/1) were prepafed daily by dilution of the stock Standard with water. A Standard solution of metabolite M3 was prepared by dissolving reference material in 0.5 ml 0.1 mol/1 sodium hydroxide and further dilution with 5 mmol/1 tetrabutyl ammonium phosphate solution. Ml was dissolved in 0.1 rnol/1 hydrochloric acid.
Processing of samples
Urine was diluted with aqueous tetrabutyl ammonium phate solution l : 40 to l: 10000 according to the expected concentration. Serum was deproteinised by mixing 0.3 ml serum with 0.6 ml acetonitrile. After centrifugation (2 min at 10 000 g) 0.3 ml superaatant was diluted with 1.2 ml aqueous tetrabutyl ammonium phosphate solution. St ndard Solutions were treated likewise. To measure the extraction rate 0.3 ml drugfree serum was spiked with 0!l ϊηΐ Standard solution (0.400 mg/1) and processed s described bef fe. For control pf precision, serum and urine pools of vario s concentrations were prepared from material obtained from volunteers.
High performance liquid chromatography (HPLC)
The 
Statistical calculations
Bivariate regression analysis was performed s previously described (13) .
Results
Development of the method
Ciprofloxacin showed a typical UV absorption spectrum with a maximum at 275 nrri. Upon excitation at 275 nm an intense blue fluorescence was observed with a maximum at 450 nm. For determination of the parent compound and the metabolite Ml (cf. fig.  1 ) detection by fluorescence was used in method A.
The main metabolite M3, however, yielded a very low fluorescence and it was therefore quantitated by UV absorption in method B. The Separation principle of both methods was reversed phase chromatography. Typical chromatograms from serum and urine show the Separation of ciprofloxacin and the metabolites Ml and m2 from endogenous compounds by method A (flg. 2 and fig. 3 ). Addition of tetrabutyl ammonium phosphate to the mobile phase was essential to avoid tailing of the peaks. Retention times of fluorescent compounds encountered in monitoring ciprofloxacin therapy of patients are given in table 1.
Only tyrosine eluted close to ciprofloxacin. However, a high serum concentration of 100 μπιοΐ/ΐ tyrosine produced a detector response equivalent to only 3 μg/l ciprofloxacin. For the elution of M3, the main metabolite in urine, the concentration of acetonitrile in the mobile phase had to be increased. Typical chromatograms obtained by method B using UV detection are shown in figure 4 . Peaks of ciprofloxacin and Ml were qualitatively identified in l ml fractions collected after chromatography by UV spectroscopy and by demonstration of antibacterial activity, and also by addition of pure substances to the sample.
Precision and accuray
Within-batch precision was measured in two serum pools, each in 10 replicates. Coefficients of Variation were 0.8% (c = 1.45 mg/1) and 2.4% (c = 0.42 mg/1) for the complete protocol. For additional results see table 2. Between-bätch precision was also measured in several serum and urine pools. Results are summarised in table 3. For serum concentrations of ciprofloxacin between 0.35 and 2.2 mg/1 coefficients of Variation varied from 4.8 to 9.3% and for urine samples coefficients of Variation were between 2.4 and 7.2%. The average recovery of ciprofloxacin from 24 spiked drug-free sera was 94.5 ± 2.6% of the added concentration (c = 1.875 mg/1). In another two series of 12 and 9 sefa, the mean recoveries were 97.2 ± 1.1% and 95.0 ± 1.8%. Recovery of ciprofloxacin from spiked urine was 99.6%.
Linearity and sensitivity
Detection limits of ciprofloxacin by method Aestimated from the smallest detectable area by the integrator -were 10 g/l in serum and 200 g/l in urine at the most sensitive setting of the fluorimeter. Detector response measured by peak areas was linearly proportional to concentration over a ränge of l to 100. For very low concentrations the injection volume could be increased from 20 to 50 withput distortion of the chromatogram. The detection limit of M3 by method B was l mg/1 in urine.
Comparison of methods
In several hundred samples from healthy volunteers concentrations of ciprofloxacin were determined both by chromatography and a conventional microbiologU cal assay. Results of bivariate regression analysis and of the sign test of paired differences are summarised in table 4. Examples of repräsentative däta sets are shown in figures 5 and 6. With the exception of two data sets obtained after a low dose (50 mg, urine) all bioassay results were significantly higher than the results obtained by chromatography. 
Interferences
Up to now, ciprofloxacin has been determined in more than 2000 samples, serum and urine, from healthy volunteers without any interference. In another study on 60 patients there was only one unexplained analytical interference in a patient with terminal renal insufficiency, who had received several other drugs simultaneously.
Discussion
Ciprofloxacin is a very potent antimicrobial agent äs compared with other groups of antibiotics (1) (2) (3) (4) (5) (6) (7) (8) . E. g., MIC90 values of 0.015 to 2 mg/1 were reported for several Gram-negative species (2). Thus, a fairly sensitive method was required for its determination in human body fluids. Furthermore it had to be taken into accourit' that ciprofloxacin is partially metabolised by the human organism (9, 10) . Some of its metabolites still showed activity in the microbiological assay used. Metabolites can also interfere in Chromatographie methods. The chemical structures of three metabolites have so far been identified (cf. fig.  1 ) (14) . Another metabolite is at present under investigation by co-workers of the manufacturer. This paper shows an additional possible metabolite called m2 the structure of which is unknown at present (cf. figs. 2 and 3). Metabolite M4 could not be detected in urine. According to 1. c. (14) its renal excretion is less than l % of the dose.
Method A uses fluorescence detection for high sensitivity and better specificity. It differs from a method first described by Gau (15) in the method of deproteinisation, the stationary phase and completeness of Separation. During the preparation of the manuscript similar Chromatographie methods for ciprofloxacin have been published (16) (17) (18) , none of which deals with the quantitation of the metabolites. The present method A separated ciprofloxacin from all known metabolites (cf. figs. 2 and 3) . It was sufficiently sensitive to measure serum concentrations up to 24 h after administration of a single oral dose of 250 mg.
Precision and recovery were satisfactory. Since the quanturn yield of the metabolites differs considerably from that of the parent compound, calibration of the fluorescence detector with pure reference substances is essential. The poor precision obtained with metabolite m2 in serum (tab. 2) was probably due to the rather small signal relative to the parent compound to which the fluorometric detector was adjusted (cf. fig. 2 ).
Method B was developed for the main metabolite M3 (oxo-ciprofloxacin), which yielded low fluoresĉ ence and was less polar (cf. fig. 4 ).
Results of the microbiological assay perfonned with split samples were generally sornewhat higher than results obtained by chromatography (tab. 4). The differences were more pronounced in urine than in serum. This is likely to be due to the presence of metabolites with antimicrobial activity, the cöncen-tration of which is usually higher in urine than in serum. In one trial a single oral dose of 250 mg ciprofloxacin was given to 10 volunteers. The mean renal elimination within 24 h was ciprofloxacin 33.6 ± 8.0% of the dose, metabolite Ml 1.3 ± 0.5% and metabolite M3 5.5 ± 8.0% (11) . Metabolite M3 had an activity of 74% relative to ciprofloxacin. Similar differences between microbiological and Chromatographie results were reported for urine (16) and for bile (18) . For this reason liquid chromatography ap^· pears the more spetific method for ciprofloxacin and is recommended both for pharmacokinetic studies and therapeutic drug monitoying. For the lätter application some caution is warranted in patients on concomitant treatment with drugs that also fluoresce. Since clinical experience with ciprofloxacin is presently still limited, indications for routine therapeutic drug monitoring are not yet defmed. Possible indications might be high dose therapy in severe infections and/or reduced elimination capacity in renal or hepatic disease.
